Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 September 2022 | Story Andrè Damons | Photo Andrè Damons
Prof Motlalepula Matsabisa
This week, Prof Motlalepula Matsabisa, will give a keynote speech on Indigenous Knowledge Systems (IKS) and Health during a session at the eighth edition of the UNGA77 Science Summit around the 77th United Nations General Assembly (SSUNGA77).

Prof Motlalepula Matsabisa, Director of Pharmacology at the University of the Free State (UFS), has been invited to give a keynote speech on Indigenous Knowledge Systems (IKS) and Health during a session at the eighth edition of the UNGA77 Science Summit around the 77th United Nations General Assembly (SSUNGA77).

While in New York, Prof Matsabisa will also meet with officials from the Wellcome Trust – a global charitable foundation – where he will present a strong and compelling motivation for the Wellcome Trust to invest in traditional medicines. Says Prof Matsabisa: “I will deliver a compelling message for investment to be made in scientific research and development around traditional medicines. This development will be piloted in a hub-and-spoke model based on the African economic blocks, with the hub being in South Africa. The returns on the investment put in this initiative will be massive for the African continent, both socially and economically, and I believe it will lead to self-sustainability and Africa being a supplier of innovations based on the science of traditional medicines.” 

SSUNGA77 is organised by Intelligence in Science and will take place from 13 to 30 September 2022. It will bring together thought leaders, scientists, technologists, innovators, policy makers, decision makers, regulators, financiers, philanthropists, journalists and editors, and community leaders to increase health science and citizen collaboration across a broad spectrum of themes, including ICT, nutrition, agriculture, health, IKS, and the environment.

Prof Matsabisa, an expert in African traditional medicine (ATM) and Chairperson of the World Health Organisation’s (WHO) Regional Expert Advisory Committee on Traditional Medicines for COVID-19 (REACT), is also the convener of this session, following his successful proposal for such a session. The session will take place in person on 20 September at the UN headquarters in New York. It is an official side event of the UN General Assembly’s 77th anniversary and will be co-sponsored by the permanent missions of Ireland, Spain, South Africa, Brazil, and Bangladesh to the UN.

His message at Science Summit

“At the end of the summit, we are to make recommendations to the UN, EU, and AU on IKS and health developmental matters. This is exciting and nerve-wracking for me, but I will remain calm knowing that I have a message to deliver to the highest global decision-making body. There can be nothing greater than presenting my talk and proposals for consideration to such a body.” 

“I will convey three simple messages, namely the importance of traditional medicines in contributing to universal health coverage, the need for Africa – through the heads of state and governments – to take seriously the local manufacturing of traditional medicines for industrialisation, economic emancipation, and responding to poverty and inequality. The third message is the need for sustained and adequate financial support by African ministries of health for the development, commercialisation, and market access to quality and well-researched, safe, and effective traditional medicines in order to contribute to priority diseases as well as responding to pandemics,” says Prof Matsabisa. 

According to him, this address at SSUNGA77 is a chance to correctly position the story on IKS with arguments based on good scientific evidence. “It means we are getting much closer to the institutionalisation and formal economic contribution of IKS to health, and that the African IKS health system is getting international recognition and acceptance,” he says.
Prof Matsabisa says he hopes the message will emerge clearly from his talk that Africa has the resources for raw materials and that the science, as well as the infrastructure, exists to develop IKS and to contribute to new health products. The spin-off is the industrialisation, job creation, and wealth generation that Africa can offer to the rest of the world.

Overall information on the summit is available here

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept